Skip to Main Content

Paper Details

Phase I Trial: Cirmtuzumab Inhibits ROR1 Signaling and Stemness Signatures in Patients with Chronic Lymphocytic Leukemia.
Cell Stem Cell
114
2018
Author NameAffiliation
Laura Z RassentiMoores Cancer Center, University of California
Minya PuMoores Cancer Center, University of California
Karen MesserMoores Cancer Center, University of California
Thomas J KippsMoores Cancer Center, University of California, USA CIRM Alpha Stem Cell Clinic at University of California, and Sanford Stem Cell Clinical Center
  • 1 - 4

Datasets